Dutch Biomarker Firm ACS Biomarker Closes Financing, Appoints New CEO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ACS Biomarker reported on Friday it has closed on a financing round and appointed a new CEO.

The amount of the funding was not disclosed. In a statement, the company, based in Maastricht, Netherlands, said it will be used to further develop its product pipeline and discover novel biomarkers "that improve diagnosis, prognosis, and management of cardiac diseases."

Funding came from Life Sciences Fund Amsterdam and Limburg Ventures, ACS said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.